New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (28 News)
Country: Germany · Primary market: Germany · EQS NID: 1518915
21 December 2022 05:00PM

Asklepios Kliniken: Asklepios signs off on first-ever commercial paper program for EUR 500 million


EQS-News: Asklepios Kliniken / Key word(s): Financing
Asklepios Kliniken: Asklepios signs off on first-ever commercial paper program for EUR 500 million

21.12.2022 / 17:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Asklepios signs off on first-ever commercial paper program for EUR 500 million

  • Opening up new sources of debt capital
  • Strategic expansion of existing financing instruments

Hamburg, 21 December 2022. Asklepios Kliniken GmbH & Co. KGaA has signed off on the company's first-ever commercial paper (CP) program for EUR 500 million, thus gaining access to an expanded financing market.

In the future, the CP program will enable the issuance of bearer bonds with terms of up to 364 days in the context of the Asklepios Group’s active liquidity management. The funds raised under the program will be used for general corporate financing.

“The adoption of the commercial paper program should be seen as part of the Asklepios Group’s long-term financing strategy,” says Hafid Rifi, Chief Financial Officer of the Asklepios Group. “Thanks particularly to the conclusion of syndicated loans and the issuance of multiple Schuldschein loans, Asklepios has broad access to the banking and promissory note markets. With the commercial paper program, we are opening up new sources of financing in the short-term range and are thus even better prepared for future macroeconomic challenges,” Rifi continues.

“With the CP program, we are expanding our financing options with a cost-effective and flexible debt capital instrument,” adds Benedikt Brörmann, Head of Corporate Finance & Treasury at Asklepios. “The program financially supplements our existing bilateral and syndicated credit lines and applies the standards of the International Capital Market Association (ICMA) for documentation.”

The establishment of the commercial paper program was guided by Commerzbank AG, which served as the arranger. The dealers under the program are BNP Paribas, Commerzbank AG, DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Landesbank Hessen-Thüringen and Landesbank Baden-Württemberg. Asklepios’s legal adviser was Linklaters LLP.

About Asklepios

Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has been developing dynamically since it was founded over 35 years ago. The Group currently has around 170 healthcare facilities throughout Germany. These include acute care hospitals of all different care levels, university hospitals, specialist clinics, psychiatric facilities, forensic institutions, rehabilitation clinics, nursing homes and medical centres. In the 2021 financial year, over 3.5 million patients were treated at the Asklepios Group’s facilities. The company has more than 67,000 employees.

IR contact
Mirjam Constantin
Head of Group ESG & Sustainability/ Manager Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 - 61462 Königstein-Falkenstein
Tel.: +49 61 74 90-1166
ir@asklepios.com

PR contact
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 - 22307 Hamburg
Tel.: +49 40 1818-82 6630
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube:

www.asklepios.com
gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken
Pflege-Blog: „Wir sind Pflege

 



21.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1518915  21.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1518915&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.